Lupin's VISUfarma Acquisition Pushed to Feb 2026; Fortifies Diabetes & Obesity Segment

• Lupin's acquisition of Amsterdam-based VISUfarma BV is now expected to close by February 28, 2026, delayed from the earlier target of end-2025.
• Lupin entered an exclusive agreement with Gan & Lee Pharmaceuticals for bofanglutide, a novel fortnightly GLP-1 receptor agonist.
• Bofanglutide targets type 2 diabetes and weight management for overweight/obese individuals, offering once-every-two-weeks convenience.
• Clinical data suggests bofanglutide provides comparable or better weight loss results than existing GLP-1 alternatives.
• The partnership strengthens Lupin's diabetes portfolio and expands its presence in India's growing obesity market.

Why It Matters: Lupin delays VISUfarma deal but strengthens its diabetes and obesity segments with a new fortnightly drug.